Search

everythinglearnresearchcommunity

for

Search:↓

Unorthodox dosing of tofacitinib and baricitinib is safe but less effective than standard dosing for treating alopecia areata in kids.

Rituximab therapy successfully treated a patient's complete body hair loss and was effective for six years.

PF-998425 is a new, effective, and non-phototoxic treatment for skin conditions related to androgens.

Triptolide effectively and safely reduces actinic keratosis lesions in mice.

Tofacitinib may help hair regrowth in alopecia areata, but more research is needed.

JAK inhibitors effectively treat severe alopecia areata with manageable side effects.

Selumetinib significantly reduced tumor size and improved vision in a child with neurofibromatosis type 1.

Licorice component glycyrrhizic acid may reduce skin side effects from cancer treatment.

Bexxar treatment led to a high response rate in patients with advanced-stage, treatment-resistant follicular lymphoma.

Tigason improved hair growth in a boy with monilethrix without side effects.

Vaccines and targeting TrxR variants can help prevent cancer and reduce metastasis.

A patient with advanced kidney cancer and no hepatitis C developed skin inflammation due to a drug called interferon alpha-2a.

EGFR cancer drugs often cause a rash, which can lead to distress and isolation, but may also improve outcomes for some cancer patients. Current treatments for the rash are limited, but a compound called menadione shows promise.

Keratin 6A increases skin inflammation, suggesting it could be a target for treating certain skin diseases.

Retinoids may help treat lupus nephritis and reduce steroid use.

Tofacitinib effectively regrows hair in alopecia areata patients, especially in younger individuals, with manageable side effects.

Tofacitinib treatment is used for teenagers with alopecia areata.

5% topical minoxidil improves hair density and quality in monilethrix patients.

CI-1033 causes skin lesions in rats, similar to humans, due to EGF receptor inhibition.

Blocking mTORC1 reduces skin tumor growth in mice.

Dabrafenib was effective and well tolerated in treating thyroid cancer with a specific mutation.

Abrocitinib is being evaluated for safety and effectiveness in treating moderate to severe atopic dermatitis.

Tebentafusp-tebn improves survival rates in uveal melanoma patients but has common side effects like rash and fatigue.

Tofacitinib and baricitinib are effective and safe for treating severe alopecia areata, especially in younger people.

A patient with alopecia areata regrew hair after taking tofacitinib and showed changes in certain blood and skin markers.

Short-term treatment with ROCKi increases skin cell growth without changing stem cell features.

A patient with Rhupus was diagnosed with Rowell syndrome and treated with various medications.

Using Janus kinase inhibitors (JAKi) in COVID-19 treatment requires careful consideration due to their immunosuppressive effects.